BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $SVA readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07055295-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Rabies Vaccine (Serum-free Vero Cell)\, Freeze-dri… readout (P3) 
 · Sinovac Biotech Co.\, Ltd $SVA
DESCRIPTION:Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Ce
 ll) in a Pre-exposure Prophylaxis Regimen\n\nPrimary completion date: 2026
 -12-30 (estimated)\nPhase 3 · Infectious · Rabies\nEnrollment: 390 · Si
 tes: 1\n\nPrimary completion = last participant's primary-endpoint data co
 llected\; topline results usually follow weeks to months later. Sponsor-re
 ported\, often an estimate. Not investment advice.\n\nhttps://datacutoff.c
 om/radar.html?nct=NCT07055295\nhttps://clinicaltrials.gov/study/NCT0705529
 5
URL:https://datacutoff.com/radar.html?nct=NCT07055295
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505836-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~experimental vaccine readout (P3) · Sinovac Biotech Co.\, Ltd $SV
 A
DESCRIPTION:Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccin
 e in Children Aged 12-23 Months\n\nPrimary completion date: 2027-01 (estim
 ated) — month only\, shown on the 1st\nPhase 3 · Infectious · Epidemic
  Meningitis\, Meningococcal Vaccines\nEnrollment: 1040 · Sites: 2\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?
 nct=NCT07505836\nhttps://clinicaltrials.gov/study/NCT07505836
URL:https://datacutoff.com/radar.html?nct=NCT07505836
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055893-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Rabies vaccine readout (P3) · Sinovac Biotech Co.\, Ltd $SVA
DESCRIPTION:Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Ce
 ll) in a Simulated Post-exposure Prophylaxis Regimen\n\nPrimary completion
  date: 2027-01-30 (estimated)\nPhase 3 · Infectious · Rabies (Healthy Vo
 lunteers)\nEnrollment: 390 · Sites: 1\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07055893\nhttps://cli
 nicaltrials.gov/study/NCT07055893
URL:https://datacutoff.com/radar.html?nct=NCT07055893
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505810-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~experimental vaccine readout (P3) · Sinovac Biotech Co.\, Ltd $SV
 A
DESCRIPTION:Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccin
 e in Children Aged 3-5 Months\n\nPrimary completion date: 2027-04 (estimat
 ed) — month only\, shown on the 1st\nPhase 3 · Infectious · Epidemic M
 eningitis\, Meningococcal Vaccines\nEnrollment: 880 · Sites: 2\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT07505810\nhttps://clinicaltrials.gov/study/NCT07505810
URL:https://datacutoff.com/radar.html?nct=NCT07505810
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505823-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~experimental vaccine readout (P3) · Sinovac Biotech Co.\, Ltd $SV
 A
DESCRIPTION:Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccin
 e in Children Aged 6-11 Months\n\nPrimary completion date: 2027-04 (estima
 ted) — month only\, shown on the 1st\nPhase 3 · Infectious · Epidemic 
 Meningitis\, Meningococcal Vaccines\nEnrollment: 1040 · Sites: 2\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT07505823\nhttps://clinicaltrials.gov/study/NCT07505823
URL:https://datacutoff.com/radar.html?nct=NCT07505823
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793227-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Inactivated Hepatitis A Vaccine (Human Diploid Ce… readout (P3) 
 · Sinovac Biotech Co.\, Ltd $SVA
DESCRIPTION:Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine\
 n\nPrimary completion date: 2027-09-15 (estimated)\nPhase 3 · Infectious 
 · Hepatitis A Vaccine\nEnrollment: 680 · Sites: 1\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07793227
 \nhttps://clinicaltrials.gov/study/NCT07793227
URL:https://datacutoff.com/radar.html?nct=NCT07793227
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
